Immunomodulatory methods using oligosaccharides

a technology of immunomodulatory methods and oligosaccharides, which is applied in the field of immunomodulatory methods using oligosaccharides, can solve the problems of not showing whether human immune cells (e.g., human immune cells in the absence of i>s. mansoni /i>infection) are responsive to lewis antigen-containing compounds, and not showing whether cell types, produce il-, and other cytokines that regulate the development o

Inactive Publication Date: 2006-02-23
HARN DONALD A +1
View PDF6 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007] Given the role of either Th1 or Th2 cells in the development or progression of many disease states, methods for influencing whether a Th1 or Th2 response is mounted are desirable for a variety of clinical situations. This invention provide methods for modulating immune responses by modulating the interaction of immune cells with a compound comprising a Lewis antigen such that production by the immune cells of at least one cytokine that regulates development of a Th1 or Th2 response is modulated. The invention is based, at least in part, on the discovery that stimulation of human immune cells, T cells or macrophages with Lewis antigen-containing conjugates results in the production of cytokines that regulate the development of Th1 or a Th2 response. Moreover, it has now been discovered that human immune cells are sensitive to stimulation by Lewisy antigen-containing conjugates, that cells from human allergy patients and cancer patients show responsiveness to Lewis antigens, that IL-4 production can be stimulated by Lewis antigen-containing conjugates and that conjugates wherein the sugars represent approximately 20-24% of the conjugate by weight, or greater, are preferred for stimulation. The immunomodulatory methods of the invention allow for an immune response to be directed to either a Th1 or a Th2 response. The ability to influence the development of either a Th1 or a Th2 response using the immunomodulatory methods of the invention is applicable to the treatment of a wide variety of disorders, including cancer, infectious diseases (e.g., HIV and tuberculosis), allergies and autoimmune diseases.

Problems solved by technology

This work, however, did not demonstrate whether human immune cells (e.g., human immune cells in the absence of S. mansoni infection) were responsive to Lewis antigen-containing compounds, nor whether cell types other than B cells, such as macrophages or T cells, could produce IL-10 in response to stimulation with compounds comprising a Lewis antigen in the absence of S. mansoni infection.
Moreover, this work did not demonstrate whether production other cytokines that regulate development of Th1 and Th2 responses, such as IL-4, could be stimulated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immunomodulatory methods using oligosaccharides
  • Immunomodulatory methods using oligosaccharides
  • Immunomodulatory methods using oligosaccharides

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0088] In this example, the ability of macrophages to produce IL-10 upon stimulation with various oligosaccharide conjugates was examined. Granuloma macrophages were prepared from C57BL / 6 mice as described in Flores Villanueva, P.O., et al. (1994) J. Immunol. 153:5190-5199 and Flores Villanueva, P.O., et al. (1994) J. Immunol. 152:1847-1855. Two million cells in 1 ml of DMEM, 10 % FCS were incubated with either no stimulant (i.e., medium alone; a negative control), lipopolysaccharide (LPS; at 20 μg / ml; a positive control), schistosome egg antigen (SEA; at 10 μg / ml), various sugars conjugated to human serum albumin (at 100 μg / ml) or human serum albumin alone (HSA; at 100 μg / ml; a negative control). The sugar conjugates tested were lacto-N-fucopentaose III (LNFP-III), lacto-N-neotetraose (LNT) and Lewisy (Ley). The oligosaccharide conjugates were obtained from Accurate Chemicals, Westbury, N.Y.

[0089] At various time points (24, 48 and 72 hours), the level of IL-10 in the supernatant ...

example 2

[0092] In this example, the ability of peripheral blood mononuclear cells (PBMCs) from humans suffering from various disorders to produce IL-10 upon stimulation with various oligosaccharide conjugates was examined. Human PBMCs were obtained from: 1) an individual who was allergic to pollen; 2) an individual suffering from lung carcinoma and 3) an individual suffering from colon carcinoma. One million PBMC in RPMI-1640 medium containing 10% human AB serum were incubated with either no stimulant (i.e., medium alone; a negative control), lipopolysaccharide (LPS; at 20 μg / ml; a positive control), various sugars conjugated to human serum albumin (at 100 μg / ml) or human serum albumin alone (HSA; at 100 μg / ml; a negative control). The sugar conjugates tested were lacto-N-fucopentaose I (LNFP-I), lacto-N-fucopentaose III (LNFP-III), lacto-N-neotetraose (LNT) and Lewisy (Ley).

[0093] After 24 hours, the level of IL-10 (in pg / ml) in the supernatant was determined by two-site ELISA as describe...

example 3

[0096] In this example, the ability of peripheral blood mononuclear cells (PBMCs) from three humans with B lymphomas to produce IL-10 upon stimulation with various oligosaccharide conjugates was examined. One million PBMC in RPMI-1640 medium containing 10% human AB serum were incubated with either no stimulant (i.e., medium alone; a negative control), lipopolysaccharide (LPS; at 20 μg / ml; a positive control), various sugars conjugated to human serum albumin (at 100 μg / ml) or human serum albumin alone (HSA; at 100 μg / ml; a negative control). The sugar conjugates tested were lacto-N-fucopentaose I (LNFP-I), lacto-N-fucopentaose III (LNFP-III), lacto-N-neotetraose (LNT), Lewisy (Ley) and lacto-N-difucohexose I (LND).

[0097] After 24 hours, the level of IL-10 (in pg / ml) in the supernatant was determined by two-site ELISA as described by in Example 2. Additionally, cellular proliferation was measured by standard 3H-thymidine uptake at 90 hours.

[0098] The results are shown below in Table...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to view more

Abstract

Methods for modulating immune responses are provided. The methods involve contacting an immune cell with an agent that modulates interaction of a compound comprising a Lewis antigen with the immune cell such that production by the immune cell of at least one cytokine that regulates development of a T helper type 1 or T helper type 2 response is modulated. In one embodiment, the agent is a stimulatory form of a compound comprising a Lewis antigen, such as a Lewisy, Lewisx or Lewisa oligosaccharide, or a derivative thereof. In another embodiment, the agent is an inhibitory form of a compound comprising a Lewis antigen, such as a Lewisy, Lewisx or Lewisa oligosaccharide, or a derivative thereof. In various embodiments, the immune cell is a human immune cell, a macrophage or a T cell. Pharmaceutical compositions for modulating immune responses are also provided.

Description

RELATED APPLICATION [0001] This application is a continuation of U.S. application Ser. No. 08 / 597518 filed Jan. 31, 1996 (now U.S. Pat. No. 6841543, issued Jan., 11, 2005), the entire contents of which are hereby incorporated by reference.GOVERNMENT FUNDING [0002] Work described herein was supported under grant AI 27448 awarded by the National Institutes of Health. The U.S. government therefore may have certain rights in this invention.BACKGROUND OF THE INVENTION [0003] The T lymphocyte compartment of the immune system can be divided into a variety of cell subsets. For example, CD4+ T cells represent the T helper cell subset, whereas CD8+ T cells represent the cytotoxic T cell subset. Additionally, CD4+ T helper cells mature into distinct subpopulations that produce different panels of cytokines: the T helper type 1 (Th1) subset produces interleukin-2 (IL-2), interferon-γ (IFN-γ) and tumor necrosis factor-↑ (TNF-β), whereas the T helper type 2 (Th2) subset produces interleukin-4 (IL...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/739A61K31/00A61K38/00A61K31/704A61K38/38A61K39/00A61K39/39A61P37/00A61P37/08
CPCA61K31/702A61K31/739A61K38/38A61K39/39Y10S530/813A61K2039/57C07H15/00C07K14/5428A61K2039/55511A61P37/00A61P37/08
Inventor HARN, DONALD A.VELUPILLAI, PALANIVEL
Owner HARN DONALD A
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap